Health Care·Biotechnology·$5.7B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.82 | N/A | -26.75% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.82 | N/A | -26.75% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management acknowledged the challenges faced during the quarter. They emphasized their commitment to ongoing projects and research.
Management did not provide specific guidance for future quarters.
The company is focused on advancing its pipeline despite the earnings miss.
PTC Therapeutics reported a larger-than-expected loss per share, which typically raises concerns among investors. However, the stock still saw a slight increase of 0.45%, likely due to investor optimism about the company's ongoing projects and pipeline advancements. The lack of revenue data and guidance leaves some uncertainty about future performance.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
ROPER TECHNOLOGIES I
Oct 30, 2017